Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation- or amplification-positive patients with bile duct cancer (iCCA)
Disease control rate of 79% with one complete response Consistent safety and tolerability profile Study…
iHerb Expands Consumer Benefits Across Asia with 618 Shopping Festival
Trade Compliance Records Addresses June 2026 Executive Order Broker Liability
Yuno Provides Corporate Update as It Advances Toward Launch, Expands Leadership Team with Talent from Binance, and Positions for Global Prediction Market Growth
Central Asia visit drives multi-sector collaboration, Business delegation signed 66 MoUs and agreements to seize Belt and Road opportunities
Custom Health Holdings Inc. Announces Completion of Plan of Arrangement